Eplerenone

Eplerenone is a steroidal mineralocorticoid receptor (MR) antagonist and the second agent approved in this pharmacological class, reaching United States Food and Drug Administration registration in 2002 (marketed as Inspra) approximately four decades after the introduction of spironolactone, the first-generation nonselective aldosterone blocker. The compound is distinguished from spironolactone by the presence of a 9-alpha,11-alpha-epoxy bridge and a 17-alpha-carbomethoxy substituent, structural modifications that confer approximately 20- to 40-fold lower binding affinity at the mineralocorticoid receptor but approximately 500- to 800-fold greater selectivity over the androgen, progesterone, and glucocorticoid receptors. This selectivity profile eliminates the gynecomastia, breast pain, menstrual irregularity, and sexual dysfunction that limit spironolactone tolerability in chronic cardiovascular and renal indications.

The clinical evidence base for eplerenone rests on two landmark randomized controlled trials. The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), published in 2003 in the New England Journal of Medicine, enrolled 6,632 patients with left ventricular dysfunction (ejection fraction 40 percent or less) 3 to 14 days after acute myocardial infarction and demonstrated that eplerenone 25 to 50 mg reduced all-cause mortality by 15 percent (relative risk 0.85; 95 percent confidence interval 0.75 to 0.96) and heart failure hospitalization by 15 percent compared to placebo on top of optimal medical therapy. The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), published in 2011 in the New England Journal of Medicine, enrolled 2,737 patients with chronic systolic heart failure (ejection fraction 35 percent or less) and New York Heart Association class II symptoms and demonstrated that eplerenone reduced the composite of cardiovascular death and heart failure hospitalization by 37 percent (hazard ratio 0.63; 95 percent confidence interval 0.54 to 0.74). These trials established eplerenone as a guideline-recommended therapy in heart failure with reduced ejection fraction and in post-myocardial infarction left ventricular dysfunction across all major international cardiovascular society guidelines.

Eplerenone is approved in the United States for hypertension and for heart failure following myocardial infarction with left ventricular dysfunction. The compound is also approved in the European Union, Japan, and multiple additional jurisdictions for heart failure with reduced ejection fraction. The pharmacokinetic profile is characterized by rapid oral absorption (time to maximum plasma concentration approximately 1.5 hours), absolute bioavailability of approximately 69 percent, elimination half-life of 4 to 6 hours, and predominant hepatic metabolism by cytochrome P450 3A4 (CYP3A4) with contributions from CYP3A5. The principal adverse event is dose-dependent hyperkalemia, occurring in approximately 5 to 10 percent of treated patients depending on baseline renal function and concurrent renin-angiotensin-aldosterone system blockade; the risk is substantially increased in patients with estimated glomerular filtration rate below 30 mL/min/1.73 m2 and in those with serum potassium above 5.0 mEq/L at baseline. The absence of clinically meaningful gynecomastia (0.7 percent versus 9 to 10 percent for spironolactone in controlled trials) is the principal tolerability advantage.

This monograph reviews the chemistry, synthesis, and structural pharmacology of eplerenone; the molecular pharmacology at the mineralocorticoid receptor in detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology in cardiac fibrosis, remodeling, and inflammatory models; the clinical evidence base across heart failure, post-myocardial infarction, hypertension, and emerging renal indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications with emphasis on CYP3A4-mediated drug-drug interactions and potassium homeostasis; adverse-event signal with focus on hyperkalemia risk stratification; and a structured comparative assessment of five mineralocorticoid receptor antagonists (spironolactone, finerenone, esaxerenone, canrenone, ocedurenone) against eplerenone on five competency standards.